Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Processa Pharmaceuticals Inc shares valued at $9,889 were purchased by Yorke Justin W on Jan 27 ’25. At $0.80 per share, Yorke Justin W acquired 12,400 shares. The insider’s holdings grew to 12,400 shares worth approximately $2728.0 following the completion of this transaction.
Also, Ng George K purchased 87,200 shares, netting a total of over 69,542 in proceeds. Following the buying of shares at $0.80 each, the insider now holds 87,200 shares.
Before that, Young David had added 124,500 shares to its account. In a trade valued at $99,289, the Pres. Research & Development bought Processa Pharmaceuticals Inc shares for $0.80 each. Upon closing the transaction, the insider’s holdings increased to 124,500 shares, worth approximately $45189.1.
As published in their initiating research note from H.C. Wainwright on April 25, 2024, Processa Pharmaceuticals Inc [PCSA] has been a Buy and the price target has been revised to $8.
Analyzing PCSA Stock Performance
On last trading session,, Processa Pharmaceuticals Inc [NASDAQ: PCSA] plunged -2.09% to $0.22. The stock’s lowest price that day was $0.21, but it reached a high of $0.2225 in the same session. During the last five days, there has been a drop of approximately -10.60%. Over the course of the year, Processa Pharmaceuticals Inc shares have dropped approximately -87.13%.
Support And Resistance Levels for Processa Pharmaceuticals Inc (PCSA)
RSI (Relative Strength Index) is 44.82 on the 14-day chart, showing neutral technical sentiment.
Is Processa Pharmaceuticals Inc subject to short interest?
Stocks of Processa Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-15 jumping by 2.37 million shares to 2.89 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 0.53 million shares. A jump of 81.74% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.06 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.06.
Which companies own the most shares of Processa Pharmaceuticals Inc (PCSA)?
In terms of Processa Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 9 in the next 12 months, up nearly 3990.91% from the previous closing price of $0.22. Analysts anticipate Processa Pharmaceuticals Inc stock to reach 9 by 2025, with the lowest price target being 9. In spite of this, 2 analysts ranked Processa Pharmaceuticals Inc stock as Buy at the end of 2025.
